Glucose injections for weight loss: correcting a persistent mix-up

Why 'glucose injections' is the wrong label for the right idea

The confusion usually starts with how these medicines are described in casual conversation or on social media. People hear "injection for weight loss" and reach for the nearest biology word they know. Glucose isn't that medicine. Neither is vitamin B6, insulin, or any other compound that sometimes surfaces in similar searches.

The licensed weight-loss injections in the UK belong to a class called GLP-1 receptor agonists. Semaglutide (Wegovy) acts on a single gut-hormone pathway; tirzepatide (Mounjaro) acts on two (GIP and GLP-1 receptors) making it the only dual-agonist option currently licensed in the UK for weight management. Both slow gastric emptying, increase the sense of fullness after eating, and reduce appetite over time. There is no glucose involved. There is no injection of sugar.

It is also worth separating these from injections that do contain semaglutide but are licensed for type 2 diabetes, such as Ozempic. Ozempic is not licensed for weight loss in the UK, and a prescriber cannot legally prescribe it for that purpose. The weight-loss version of semaglutide is Wegovy, in a different dose range. The NHS medicines page on tirzepatide sets out what these medicines are, how they work, and their common side effects in plain terms.

What the clinical evidence actually shows

The results from properly conducted trials are striking enough without the confusion of wrong names. In the SURMOUNT-1 trial (2,539 adults with obesity, 72 weeks), participants taking tirzepatide at its highest dose lost around 20–21% of body weight on average alongside lifestyle changes. That figure comes from a peer-reviewed paper in the New England Journal of Medicine and formed the basis for NICE's recommendation of tirzepatide in December 2024. The STEP 1 trial of semaglutide 2.4mg showed roughly 15% average weight loss over 68 weeks in a similar population.

Neither figure is a guarantee of what any individual will achieve, weight loss on these medicines varies, and a clinical review matters precisely because some people have conditions that change the picture. But the evidence base is substantial, and it explains why these medicines have transformed how obesity is managed clinically. If you want to understand how the two licensed options compare, the full comparison of UK weight-loss injections covers the key differences between them.

Questions about price are entirely reasonable, and you can read a plain breakdown on the weight-loss injections price guide, it covers what legitimate private prescriptions typically cost and what an all-in price should include.

Who these injections are licensed for (and what that assessment involves

Under the medicines' UK licences, tirzepatide and semaglutide are available to adults with a BMI of 30 or above, or from 27 upward if at least one weight-related condition is present) such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A prescriber looks at the full picture: current medicines, medical history, and whether any contraindications rule these treatments out.

Pregnancy, breastfeeding, and trying to conceive are all situations where these medicines are not recommended. The same applies to anyone under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma) are contraindications that a prescriber will screen for. The eligibility guide for weight-loss injections explains the BMI thresholds and conditions in more detail.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation, not software, not a triage checklist. Our clinical team's approach is described on the clinical team page. Once approved, your treatment ships the same day (order before 12pm Monday to Friday) and arrives in a plain, unbranded box via DPD tracked delivery, the pen itself is pre-filled and ready to use from the fridge.

A note on injections that are not what they claim to be

The MHRA has issued repeated warnings about fake weight-loss pens sold through social media and unregistered online sellers. Counterfeit pens have been found containing insulin, a serious, potentially life-threatening substitution. Any seller offering these medicines without requiring a prescription is operating outside UK law, and the price is never worth that risk.

The only safe route is a prescription issued after a proper clinical assessment, dispensed by a pharmacy registered with the GPhC. You can verify any online pharmacy instantly at the GPhC register. Suspect sellers can be reported via the MHRA Yellow Card scheme. If you are considering treatment, the right starting point is a conversation with a prescriber who can review your health in full. Speak to our prescribers and we can assess whether one of the licensed options is right for you.